The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning

Next-generation characterization of the Cancer Cell Line Encyclopedia

(2019) Mahmoud Ghandi et al.   NATURE

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematological Cancers: Results of a Phase I Dose Escalation Study

(2019) Amit Khot et al.   Cancer Discovery

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

(2019) Ann Lin et al.   Science Translational Medicine

A LINE1-Nucleolin Partnership Regulates Early Development and ESC Identity

(2018) Michelle Percharde et al.   CELL

mTORC1 Controls Phase Separation and the Biophysical Properties of the Cytoplasm by Tuning Crowding

(2018) M. Delarue et al.   CELL

Nucleolar residence of the seckel syndrome protein TRAIP is coupled to ribosomal DNA transcription

(2018) Yangzi Chen et al.   NUCLEIC ACIDS RESEARCH

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

(2017) Peter M Bruno et al.   NATURE MEDICINE

The target landscape of clinical kinase drugs

(2017) Susan Klaeger et al.   SCIENCE

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours

(2017) Hong Xu et al.   Nature Communications

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

(2017) Ruogu Qi et al.   Nature Communications

The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells

(2016) Paul B. Cressey et al.   CHEMBIOCHEM

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines

(2016) Channing Yu et al.   NATURE BIOTECHNOLOGY

A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy

(2015) Samuel G. Awuah et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

(2015) J. R. Devlin et al.   Cancer Discovery

p53 and ribosome biogenesis stress: The essentials

(2014) Lior Golomb et al.   FEBS LETTERS

Topoisomerase IIα promotes activation of RNA polymerase I transcription by facilitating pre-initiation complex formation

(2013) Swagat Ray et al.   Nature Communications

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

Understanding resistance to combination chemotherapy

(2012) Justin R. Pritchard et al.   DRUG RESISTANCE UPDATES

Predicting cancer drug mechanisms of action using molecular network signatures

(2012) Justin R. Pritchard et al.   Molecular BioSystems

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Defining principles of combination drug mechanisms of action

(2012) J. R. Pritchard et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

(2012) Mustapha Haddach et al.   ACS Medicinal Chemistry Letters

Expression Profiling of Liposarcoma Yields a Multigene Predictor of Patient Outcome and Identifies Genes That Contribute to Liposarcomagenesis

(2011) R. M. Gobble et al.   CANCER RESEARCH

Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer

(2011) Lee M. Krug et al.   Journal of Thoracic Oncology

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo

(2011) Kristen L. Meerbrey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Modulatory profiling identifies mechanisms of small molecule-induced cell death

(2011) A. J. Wolpaw et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide

(2011) C.-C. Wu et al.   SCIENCE

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

(2010) Denis Drygin et al.   CANCER RESEARCH

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

(2010) E. J. Walsby et al.   HAEMATOLOGICA

Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi

(2010) Johannes Zuber et al.   NATURE BIOTECHNOLOGY

A mammalian functional-genetic approach to characterizing cancer therapeutics

(2010) Hai Jiang et al.   Nature Chemical Biology

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II

(2010) Rachael E. Hawtin et al.   PLoS One

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

(2008) Darren J. Burgess et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA